Divi’s Laboratories looks up after strong Q1FY17

Divi’s Laboratories has declared its Q1FY17 results on Friday. The company’s revenue has increased by 24.65 per cent to Rs 1008 crore in Q1FY17 as compared to same period in previous fiscal. Its EBITDA too has risen by 33.77 per cent to Rs 404 crore in Q1FY17 as compared to same period in previous financial year. Divi’s Laboratories’ EBITDA margin has expanded by 273 basis points to 40.05 per cent in Q1FY17 on a yearly basis. The company’s net profit also has increased by 23.10 per cent to Rs 302 crore in Q1FY17 as compared to same period in previous fiscal. However, its net profit margin has contracted by 38 basis points to 29.94 per cent in Q1FY17 on a yearly basis.

The share price of Divi’s Laboratories has increased by 6.41 per cent on bourses in early trades; and is trading at Rs 1260 on an intraday basis.

Divi's Laboratories is engaged in the manufacturing of generic active pharmaceutical ingredients (APIs), custom synthesis of active ingredients for companies, other specialty chemicals and nutraceuticals. The company's main manufacturing and research and development facilities are located in the state of Andhra Pradesh and Telangana.